Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days the report can be obtained for the test ERBB2 Mutation Analysis Test by NGS (Hotspot Regions) is 14 days.

What are the prerequisites for the test ERBB2 Mutation Analysis Test by NGS (Hotspot Regions)

  • Specimen Type: Formalin-Fixed Paraffin-Embedded (FFPE) tissue block or slides
  • Specimen Requirements: 1 H&E slide + 7-10 unstained slides at 5-10 microns or 1 FFPE tissue block
  • Specimen Stability: FFPE blocks and slides are stable for 2 years at room temperature
  • Turnaround Time: 7-10 days
  • Methodology: Next Generation Sequencing (NGS)
  • Targeted Regions: Hotspot regions of ERBB2 gene

What are the measure values for the test ERBB2 Mutation Analysis Test by NGS (Hotspot Regions)

  • Test Name: ERBB2 Mutation Analysis Test by NGS (Hotspot Regions)
  • Measure Values:
    • Gene: ERBB2
    • Method: Next-Generation Sequencing (NGS)
    • Regions Analyzed: Hotspot Regions
    • Results: Mutation status in hotspot regions of ERBB2 gene reported
    • Interpretation: Results interpreted based on presence or absence of mutations in hotspot regions
    • Clinical Significance: Detection of mutations in ERBB2 gene can have implications for targeted therapy in cancer patients

What does this test ERBB2 Mutation Analysis Test by NGS (Hotspot Regions) identify?

Test: ERBB2 Mutation Analysis Test by NGS (Hotspot Regions)

The ERBB2 Mutation Analysis Test by Next Generation Sequencing (NGS) specifically targets hotspot regions within the ERBB2 gene. This test is designed to identify mutations or alterations in the ERBB2 gene that may be associated with various types of cancers, particularly breast cancer.

ERBB2, also known as HER2, is a gene that encodes a protein involved in cell growth and division. Mutations in the ERBB2 gene can lead to uncontrolled cell growth, potentially contributing to the development and progression of cancer.

By analyzing hotspot regions within the ERBB2 gene using NGS technology, this test can provide detailed information about specific mutations present in the gene. This information can be valuable for guiding treatment decisions, predicting response to targeted therapies, and understanding the underlying genetic factors contributing to cancer development.

Why is this test ERBB2 Mutation Analysis Test by NGS (Hotspot Regions) taken?

ERBB2 Mutation Analysis Test by NGS (Hotspot Regions) is taken to detect mutations in the ERBB2 gene that may be associated with certain types of cancer, such as breast cancer. This test uses Next-Generation Sequencing (NGS) technology to analyze specific regions of the ERBB2 gene known to be hotspot regions for mutations.

Identifying mutations in the ERBB2 gene can help healthcare providers make more informed decisions about treatment options for patients with cancer. For example, certain mutations in the ERBB2 gene may make a patient eligible for targeted therapies that specifically target the mutated gene, leading to more effective and personalized treatment.

Overall, the ERBB2 Mutation Analysis Test by NGS (Hotspot Regions) is an important tool in the diagnosis and treatment of cancer, as it provides valuable information about the genetic makeup of a patient's tumor and helps guide personalized treatment strategies.

No FAQs available.

Customer Google Rating